Ocera Therapeutics Inc  

(Public, NASDAQ:OCRX)   Watch this stock  
Find more results for ocrx
Real-time:   4:00PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.52 - 2.95
Open     -
Vol / Avg. 0.00/913,190.00
Mkt cap 47.46M
P/E     -
Div/yield     -
EPS -0.97
Shares 26.51M
Beta 2.46
Inst. own 27%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -4416.26%
Operating margin - -4249.59%
EBITD margin - -4242.36%
Return on average assets -134.92% -72.32%
Return on average equity -383.51% -114.13%
Employees 19 -
CDP Score - -


555 Twin Dolphin Dr Ste 615
REDWOOD CITY, CA 94065-2130
United States - Map
+1-650-4750158 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.